-
Je něco špatně v tomto záznamu ?
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
JC. Bennett, M. Deloria Knoll, EW. Kagucia, M. Garcia Quesada, SL. Zeger, MK. Hetrich, Y. Yang, C. Herbert, A. Ogyu, AL. Cohen, I. Yildirim, BA. Winje, A. von Gottberg, D. Viriot, M. van der Linden, P. Valentiner-Branth, S. Suga, A. Steens, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
Grantová podpora
001
World Health Organization - International
NLK
ProQuest Central
od 2001-08-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2001-08-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2001-08-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2001-08-01 do Před 2 měsíci
- MeSH
- celosvětové zdraví * MeSH
- dítě MeSH
- dospělí MeSH
- incidence MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- novorozenec MeSH
- pneumokokové infekce * prevence a kontrola epidemiologie MeSH
- pneumokokové vakcíny * aplikace a dávkování MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- séroskupina MeSH
- Streptococcus pneumoniae * klasifikace imunologie MeSH
- vakcíny konjugované aplikace a dávkování MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages. METHODS: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%. Annual incidence rate ratios (IRRs) were estimated comparing the incidence before any PCV with each year post-PCV10 or post-PCV13 introduction using Bayesian multi-level, mixed-effects Poisson regressions, by site and age group. All site-weighted average IRRs were estimated using linear mixed-effects regression, stratified by product and previous seven-valent PCV (PCV7) effect (none, moderate, or substantial). FINDINGS: Analyses included 32 PCV13 sites (488 758 cases) and 15 PCV10 sites (46 386 cases) in 30 countries, primarily high income (39 sites), using booster dose schedules (41 sites). By 6 years after PCV10 or PCV13 introduction, IPD due to PCV10-type serotypes and PCV10-related serotype 6A declined substantially for both products (age <5 years: 83-99% decline; ≥65 years: 54-96% decline). PCV7-related serotype 19A increases before PCV10 or PCV13 introduction were reversed at PCV13 sites (age <5 years: 61-79% decline relative to before any PCV; age ≥65 years: 7-26% decline) but increased at PCV10 sites (age <5 years: 1·6-2·3-fold; age ≥65 years: 3·6-4·9-fold). Serotype 3 IRRs had no consistent trends for either product or age group. Non-PCV13-type IPD increased similarly for both products (age <5 years: 2·3-3·3-fold; age ≥65 years: 1·7-2·3-fold). Despite different serotype 19A trends, all-serotype IPD declined similarly between products among children younger than 5 years (58-74%); among adults aged 65 years or older, declines were greater at PCV13 (25-29%) than PCV10 (4-14%) sites, but other differences between sites precluded attribution to product. INTERPRETATION: Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.
Centre for Disease Control Department of Health and Community Services Darwin NT Australia
Centre for Global Health Research Kenya Medical Research Institute Kisumu Kenya
Child Health Research Foundation Dhaka Bangladesh
CIBER Epidemiology and Public Health Madrid Spain
Communicable Diseases Centre National Institute of Public Health Ljubljana Slovenia
Department for Vaccine Preventable Diseases National Public Health Organization Athens Greece
Department of Clinical Microbiology Landspitali The National University Hospital Reykjavik Iceland
Department of Health Security Finnish Institute for Health and Welfare Helsinki Finland
Department of Immunizations Vaccines and Biologicals WHO Geneva Switzerland
Department of Infectious Diseases Italian National Institute of Health Rome Italy
Department of Microbiology Immunology and Transplantation KU Leuven Leuven Belgium
Department of Paediatrics University of Melbourne Parkville VIC Australia
Department of Pediatrics University of Calgary Calgary AB Canada
Department of Pediatrics Yale New Haven Children's Hospital New Haven CT USA
Department of Social and Preventive Medicine Laval University Quebec QC Canada
Epidemiology Department Epiconcept Paris France
Epidemiology Team Institute of Environmental Science and Research Wellington New Zealand
European Centre for Disease Prevention and Control Solna Sweden
Faculty of Health Sciences Oslo Metropolitan University Oslo Norway
Faculty of Infectious and Tropical Diseases London School of Hygiene and Tropical Medicine London UK
French Public Health Agency Saint Maurice France
Health Protection Surveillance Centre Dublin Ireland
Health Sciences Unit Faculty of Social Sciences Tampere University Tampere Finland
Immunisation and Countermeasures Division UK Health Security Agency London UK
Infectious Disease Epidemiology and Prevention Statens Serum Institut Copenhagen Denmark
Infectious Diseases Research Unit Mohammed 6 Center for Research and Innovation Rabat Morocco
Institute of Public Health Riga Stradins University Riga Latvia
Instituto de Salud Pública de Chile Santiago Chile
Johns Hopkins Bloomberg School of Public Health Baltimore MD USA
Malawi Liverpool Wellcome Programme Blantyre Malawi
Murdoch Children's Research Institute Parkville VIC Australia
National Center of Communicable Diseases Ministry of Health Ulaanbaatar Mongolia
National Institute of Public Health Prague Czech Republic
National Reference Centre for Bacterial Meningitis National Medicines Institute Warsaw Poland
National Reference Centre for Streptococcus Pneumoniae University Hospitals Leuven Leuven Belgium
New Vaccines Group Murdoch Children's Research Institute Parkville VIC Australia
Public Health Institute of Navarre IdiSNA Pamplona Spain
Public Health Scotland Glasgow UK
Regional Public Health Laboratory General Directorate of Public Health Madrid Spain
Singapore Ministry of Health Communicable Diseases Division Singapore
Surveillance and Public Health Emergency Response Public Health Agency of Catalonia Barcelona Spain
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25009380
- 003
- CZ-PrNML
- 005
- 20250429134911.0
- 007
- ta
- 008
- 250415s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1473-3099(24)00665-0 $2 doi
- 035 __
- $a (PubMed)39706204
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bennett, Julia C $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: jbenne63@jhu.edu
- 245 10
- $a Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis / $c JC. Bennett, M. Deloria Knoll, EW. Kagucia, M. Garcia Quesada, SL. Zeger, MK. Hetrich, Y. Yang, C. Herbert, A. Ogyu, AL. Cohen, I. Yildirim, BA. Winje, A. von Gottberg, D. Viriot, M. van der Linden, P. Valentiner-Branth, S. Suga, A. Steens, A. Skoczynska, N. Sinkovec Zorko, JA. Scott, C. Savulescu, L. Savrasova, JC. Sanz, F. Russell, LJ. Ricketson, R. Puentes, JP. Nuorti, J. Mereckiene, K. McMahon, A. McGeer, L. Mad'arová, GA. Mackenzie, L. MacDonald, T. Lepp, SN. Ladhani, KG. Kristinsson, J. Kozakova, NP. Klein, S. Jayasinghe, PL. Ho, M. Hilty, RS. Heyderman, M. Hasanuzzaman, LL. Hammitt, M. Guevara, M. Grgic-Vitek, R. Gierke, T. Georgakopoulou, Y. Galloway, I. Diawara, S. Desmet, P. De Wals, R. Dagan, E. Colzani, C. Cohen, P. Ciruela, U. Chuluunbat, G. Chan, R. Camilli, MG. Bruce, MC. Brandileone, G. Bigogo, K. Ampofo, KL. O'Brien, DR. Feikin, K. Hayford, PSERENADE Team
- 520 9_
- $a BACKGROUND: Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on invasive pneumococcal disease (IPD) incidence in all ages. METHODS: Serotype-specific IPD cases and population denominators were obtained directly from surveillance sites using PCV10 or PCV13 in their national immunisation programmes and with a primary series uptake of at least 50%. Annual incidence rate ratios (IRRs) were estimated comparing the incidence before any PCV with each year post-PCV10 or post-PCV13 introduction using Bayesian multi-level, mixed-effects Poisson regressions, by site and age group. All site-weighted average IRRs were estimated using linear mixed-effects regression, stratified by product and previous seven-valent PCV (PCV7) effect (none, moderate, or substantial). FINDINGS: Analyses included 32 PCV13 sites (488 758 cases) and 15 PCV10 sites (46 386 cases) in 30 countries, primarily high income (39 sites), using booster dose schedules (41 sites). By 6 years after PCV10 or PCV13 introduction, IPD due to PCV10-type serotypes and PCV10-related serotype 6A declined substantially for both products (age <5 years: 83-99% decline; ≥65 years: 54-96% decline). PCV7-related serotype 19A increases before PCV10 or PCV13 introduction were reversed at PCV13 sites (age <5 years: 61-79% decline relative to before any PCV; age ≥65 years: 7-26% decline) but increased at PCV10 sites (age <5 years: 1·6-2·3-fold; age ≥65 years: 3·6-4·9-fold). Serotype 3 IRRs had no consistent trends for either product or age group. Non-PCV13-type IPD increased similarly for both products (age <5 years: 2·3-3·3-fold; age ≥65 years: 1·7-2·3-fold). Despite different serotype 19A trends, all-serotype IPD declined similarly between products among children younger than 5 years (58-74%); among adults aged 65 years or older, declines were greater at PCV13 (25-29%) than PCV10 (4-14%) sites, but other differences between sites precluded attribution to product. INTERPRETATION: Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites. FUNDING: Bill & Melinda Gates Foundation as part of the WHO Pneumococcal Vaccines Technical Coordination Project.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a pneumokokové vakcíny $x aplikace a dávkování $7 D022242
- 650 12
- $a pneumokokové infekce $x prevence a kontrola $x epidemiologie $7 D011008
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a mladý dospělý $7 D055815
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a incidence $7 D015994
- 650 12
- $a celosvětové zdraví $7 D014943
- 650 12
- $a Streptococcus pneumoniae $x klasifikace $x imunologie $7 D013296
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a séroskupina $7 D065288
- 650 _2
- $a vakcíny konjugované $x aplikace a dávkování $7 D018074
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a novorozenec $7 D007231
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Deloria Knoll, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: mknoll2@jhu.edu
- 700 1_
- $a Kagucia, Eunice W $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
- 700 1_
- $a Garcia Quesada, Maria $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Zeger, Scott L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Hetrich, Marissa K $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Yang, Yangyupei $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Herbert, Carly $u UMass Chan Medical School, Worcester, MA, USA
- 700 1_
- $a Ogyu, Anju $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Cohen, Adam L $u Department of Immunizations, Vaccines and Biologicals, WHO, Geneva, Switzerland; Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
- 700 1_
- $a Yildirim, Inci $u Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT, USA
- 700 1_
- $a Winje, Brita A $u Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway
- 700 1_
- $a von Gottberg, Anne $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 700 1_
- $a Viriot, Delphine $u French Public Health Agency, Saint-Maurice, France
- 700 1_
- $a van der Linden, Mark $u Reference Laboratory for Streptococci, Department of Medical Microbiology, University Hospital RWTH Aachen, Aachen, Germany
- 700 1_
- $a Valentiner-Branth, Palle $u Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- 700 1_
- $a Suga, Shigeru $u Infectious Disease Center and Department of Clinical Research, National Hospital Organization Mie Hospital, Tsu, Japan
- 700 1_
- $a Steens, Anneke $u Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands
- 700 1_
- $a Skoczynska, Anna $u National Reference Centre for Bacterial Meningitis, National Medicines Institute, Warsaw, Poland
- 700 1_
- $a Sinkovec Zorko, Nadja $u Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
- 700 1_
- $a Scott, J Anthony $u Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
- 700 1_
- $a Savulescu, Camelia $u Epidemiology Department, Epiconcept, Paris, France
- 700 1_
- $a Savrasova, Larisa $u Institute of Public Health, Riga Stradins University, Riga, Latvia
- 700 1_
- $a Sanz, Juan Carlos $u Regional Public Health Laboratory, General Directorate of Public Health, Madrid, Spain
- 700 1_
- $a Russell, Fiona $u Centre for International Child Health, WHO Collaborating Centre for Research and Training in Child and Neonatal Health, University of Melbourne, Parkville, VIC, Australia; Murdoch Children's Research Institute, Parkville, VIC, Australia
- 700 1_
- $a Ricketson, Leah J $u Department of Pediatrics, University of Calgary, Calgary, AB, Canada
- 700 1_
- $a Puentes, Rodrigo $u Instituto de Salud Pública de Chile, Santiago, Chile
- 700 1_
- $a Nuorti, J Pekka $u Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland; Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland
- 700 1_
- $a Mereckiene, Jolita $u Health Protection Surveillance Centre, Dublin, Ireland
- 700 1_
- $a McMahon, Kimberley $u Centre for Disease Control, Department of Health and Community Services, Darwin, NT, Australia
- 700 1_
- $a McGeer, Allison $u Toronto Invasive Bacterial Diseases Network and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
- 700 1_
- $a Mad'arová, Lucia $u National Reference Centre for Pneumococcal and Haemophilus Diseases, Regional Authority of Public Health, Banská Bystrica, Slovakia
- 700 1_
- $a Mackenzie, Grant A $u Department of Paediatrics, University of Melbourne, Parkville, VIC, Australia; Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, The Gambia; New Vaccines Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
- 700 1_
- $a MacDonald, Laura $u Public Health Scotland, Glasgow, UK
- 700 1_
- $a Lepp, Tiia $u Department of Communicable Disease and Control and Health Protection, Public Health Agency of Sweden, Solna, Sweden
- 700 1_
- $a Ladhani, Shamez N $u Immunisation and Countermeasures Division, UK Health Security Agency, London, UK
- 700 1_
- $a Kristinsson, Karl G $u Department of Clinical Microbiology, Landspitali-The National University Hospital, Reykjavik, Iceland
- 700 1_
- $a Kozakova, Jana $u National Institute of Public Health, Prague, Czech Republic
- 700 1_
- $a Klein, Nicola P $u Vaccine Study Center, Kaiser Permanente, Oakland, CA, USA
- 700 1_
- $a Jayasinghe, Sanjay $u National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, Children's Hospital Westmead Clinical School, Faculty of Medicine and Health, University of Sydney, Westmead, NSW, Australia
- 700 1_
- $a Ho, Pak-Leung $u Department of Microbiology and Carol Yu Centre for Infection, Queen Mary Hospital, The University of Hong Kong, Hong Kong Special Administrative Region, China
- 700 1_
- $a Hilty, Markus $u Swiss National Reference Centre for Invasive Pneumococci, Institute for Infectious Diseases, University of Bern, Bern, Switzerland
- 700 1_
- $a Heyderman, Robert S $u Malawi Liverpool Wellcome Programme, Blantyre, Malawi; NIHR Global Health Research Unit on Mucosal Pathogens, Division of Infection and Immunity, University College London, London, UK
- 700 1_
- $a Hasanuzzaman, Md $u Child Health Research Foundation, Dhaka, Bangladesh
- 700 1_
- $a Hammitt, Laura L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA; Epidemiology and Demography Department, KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Coast, Kilifi, Kenya
- 700 1_
- $a Guevara, Marcela $u CIBER Epidemiology and Public Health, Madrid, Spain; Public Health Institute of Navarre-IdiSNA, Pamplona, Spain
- 700 1_
- $a Grgic-Vitek, Marta $u Communicable Diseases Centre, National Institute of Public Health, Ljubljana, Slovenia
- 700 1_
- $a Gierke, Ryan $u Division of Bacterial Diseases, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA
- 700 1_
- $a Georgakopoulou, Theano $u Department for Vaccine Preventable Diseases, National Public Health Organization, Athens, Greece
- 700 1_
- $a Galloway, Yvonne $u Epidemiology Team, Institute of Environmental Science and Research, Wellington, New Zealand
- 700 1_
- $a Diawara, Idrissa $u Mohammed VI University of Sciences and Health, Mohammed VI Higher Institute of Biosciences and Biotechnologies (UM6SS), Casablanca, Morocco; Infectious Diseases Research Unit, Mohammed VI Center for Research and Innovation (CM6RI), Rabat, Morocco
- 700 1_
- $a Desmet, Stefanie $u Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium; National Reference Centre for Streptococcus Pneumoniae, University Hospitals Leuven, Leuven, Belgium
- 700 1_
- $a De Wals, Philippe $u Department of Social and Preventive Medicine, Laval University, Quebec, QC, Canada
- 700 1_
- $a Dagan, Ron $u The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- 700 1_
- $a Colzani, Edoardo $u European Centre for Disease Prevention and Control, Solna, Sweden
- 700 1_
- $a Cohen, Cheryl $u Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 700 1_
- $a Ciruela, Pilar $u CIBER Epidemiology and Public Health, Madrid, Spain; Surveillance and Public Health Emergency Response, Public Health Agency of Catalonia, Barcelona, Spain
- 700 1_
- $a Chuluunbat, Urtnasan $u National Center of Communicable Diseases, Ministry of Health, Ulaanbaatar, Mongolia
- 700 1_
- $a Chan, Guanhao $u Singapore Ministry of Health, Communicable Diseases Division, Singapore
- 700 1_
- $a Camilli, Romina $u Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy
- 700 1_
- $a Bruce, Michael G $u Arctic Investigations Program, Division of Infectious Disease Readiness and Innovation, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Anchorage, AK, USA
- 700 1_
- $a Brandileone, Maria-Cristina C $u National Laboratory for Meningitis and Pneumococcal Infections, Center of Bacteriology, Institute Adolfo Lutz, São Paulo, Brazil
- 700 1_
- $a Bigogo, Godfrey $u Centre for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya
- 700 1_
- $a Ampofo, Krow $u Division of Pediatric Infectious Diseases, Department of Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, USA
- 700 1_
- $a O'Brien, Katherine L $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 700 1_
- $a Feikin, Daniel R $u Department of Immunizations, Vaccines and Biologicals, WHO, Geneva, Switzerland
- 700 1_
- $a Hayford, Kyla $u Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 710 2_
- $a PSERENADE Team
- 773 0_
- $w MED00006437 $t Lancet. Infectious diseases $x 1474-4457 $g Roč. 25, č. 4 (2025), s. 457-470
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39706204 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250415 $b ABA008
- 991 __
- $a 20250429134906 $b ABA008
- 999 __
- $a ok $b bmc $g 2311015 $s 1246461
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 25 $c 4 $d 457-470 $e 20241217 $i 1474-4457 $m Lancet. Infectious diseases $n Lancet Infect Dis $x MED00006437
- GRA __
- $a 001 $p World Health Organization $2 International
- LZP __
- $a Pubmed-20250415
